DOCSLIB.ORG

Case Series, Descriptive, and Cross-Sectional Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case Series, Descriptive, and Cross-Sectional Studies Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies Population of patients with condition of interest Sample Sample Case Series, Descriptive, Group 1 Group 2 and Cross-Sectional Studies Bias External Validity Internal Validity Pawin Numthavaj, M.D. Section for Clinical Epidemiology & Biostatistics Chance Faculty of Medicine Ramathibodi Hospital Mahidol University August 2014 Conclusion Hierarchy of evidence Natural Clinical Research Assign Exposure Exposure Observational Studies Experimental Studies No With comparator comparator Systematic Review & Meta-analysis Descriptive Analytic Randomized Controlled Trials Randomized Controlled Trials Case Study Cross-Sectional Nonrandomized Non-randomized Intervention Studies Controlled Trials Case Series Cohort Observational Studies Cross-Sectional Case-Control Non-experimental Studies Hybrid Studies (Nested CC, Case-Cohort) Expert Opinion BMJ 2001;323:334.1 Descriptive Studies • Concerned about disease burden • Attempt to answer question • Who? • What? • Where? • When? • “First ideas” about causality and generate Case report and Case series hypothesis for further studies 1 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies Case report and Case series Example • Detailed description of one or more cases of a • Description of series of infants born with disease that are unusual for some reason congenital cataracts and cardiac abnormalities • Never seen before in Australia (Gregg 1941) • Occur in unexpected individuals • Severe epidemic of rubella 6-9 mo. before children • Occur in unexpected places born • Now: we know that rubella affect babies born from infected mother Propranolol vs. Infantile Hemangioma • Identify potential health problems in outbreaks: • Léauté-Labrèze 2008. Case report of successful SARS, bird flu, swine flu treatment of a child with infantile hemangioma with obstructive cardiomyopathy with propranolol Léauté-Labrèze C et al. N Engl J Med 2008;358:2649-2651. Propranolol vs. Infantile Hemangioma • 2008: First case report • Almost everyone still use Steroids • Multiple case reports follow • 2011: First RCT • Positive result • Multiple RCTs follow • 2013: Meta-analysis Cross-sectional Studies • Nowadays • Almost everyone now try propranolol first 2 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies now time Principle of X-Sectional Studies Exposure Outcome Exposure Outcome Cohort • Conducted at “single point” in time • (Or a relatively short period) • “Snapshot” of population Exposure Outcome • Exposure and Outcome measured at one point in time or over a period* Exposure Outcome Case Control • Often in the same time • Can be descriptive or analytic Outcome Outcome Outcome • Depend on design Cross • Prevalence study (descriptive) Sectional • Comparison of prevalence among exposed and non Exposure Exposure Exposure exposed (analytic) Population Population Sample Sample Describe Male 53% Mean age 45.30 yr Analyze Smoke 30% Mean SBP 143 mmHg + Exposure , – Outcome One time SD SBP 12 mmHg One time + Exposure , + Outcome Measurement Mean DBP 84 mmHg Measurement – Exposure, – Outcome SD SBP 11 mmHg – Exposure, + Outcome Example Snapshots of Disease • Prevalence of disease • Prevalence of Hand-Foot-Mouth disease in Bangkok • Morbidity Survey • Prevalence of post anesthetic spinal headache • Distribution • Mean and SD of length of descending branch of lateral circumflex femoral artery in Thai people Prevalence of malaria 1995 1996 1997 3 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies Descriptive Cross-Sectional Studies Prevalence vs. Incidence • What they can do • Prevalence • Trend analysis (forecasting) • Fraction of a group of people possessing a clinical • Planning condition/outcome at given point in time • Clue about cause (generate hypothesis) • Incidence • What they CANNOT do • Fraction of group of people initially free of outcome • Conclusion about cause of disease but develops condition over a given period of time • Over- or misinterpretation of data Problem about descriptive data • Vitamin C reduce URI symptom 70% • Placebo reduce URI symptom 60% • Which one should we use? Descriptive vs. Analytic Analytic Cross-Sectional Studies • Prevalence • Measurement of association Descriptive Analytic • Prevalence ratio • Prevalence odds ratio • Diagnostic studies • Sensitivity •Describe •Explain • Specificity • Predictive values • Accuracy 4 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies Analytic Cross-Sectional Studies 2x2 Table Disease No Disease Population (Outcome+) (Outcome−) Exposure+ Outcome+ Sample Exposure+ Risk factor Outcome− (Exposure+) Exposure− Outcome+ One time Measurement Exposure− No Risk factor Outcome− (Exposure−) Disease (O+)No Disease(O−) O+ O− E+ A B A+B Risk factor A+B (E+) A B E− C D C+D A+C B+D A+B+C+D No Risk factor C+D A+C (E−) C D Prevalence (of disease) = A+B+C+D A+C B+D A+B+C+D Disease No Disease Measurement of Association Risk factor A+B A B • Prevalence Ratio (PR) No • Prevalence Odds Ratio (POR) Risk factor C+D C D A+C B+D A+B+C+D Prevalence of disease A among exposured (E+) = A+B Prevalence of disease C among unexposured (E-) = C+D 5 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies 1. Prevalence Ratio 2. Prevalence Odds Ratio Odds of Exposure among Cases 퐸푥푝표푠푒푑 푐푎푠푒푠 푈푛푒푥푝표푠푒푑 푐푎푠푒푠 푃푟푒푣푎푙푒푛푐푒 표푓 푑푖푠푒푎푠푒 푎푚표푛푔 푒푥푝표푠푢푟푒 = ÷ = 퐴푙푙 푐푎푠푒푠 퐴푙푙 푐푎푠푒푠 푃푟푒푣푎푙푒푛푐푒 표푓 푑푖푠푒푎푠푒 푎푚표푛푔 푛표푛 푒푥푝표푠푢푟푒 퐴 퐶 = ÷ 퐴 퐶 퐴 + 퐶 퐴 + 퐶 = ÷ = 퐴 ÷ 퐶 퐴 + 퐵 퐶 + 퐷 Odds of Exposure among Non-cases 퐸푥푝표푠푒푑 푛표푛푐푎푠푒푠 푈푛푒푥푝표푠푒푑 푛표푛푐푎푠푒푠 = ÷ 퐴푙푙 푛표푛푐푎푠푒푠 퐴푙푙 푛표푛푐푎푠푒푠 퐵 퐷 = ÷ 퐵 + 퐷 퐵 + 퐷 = 퐵 ÷ 퐷 푂푑푑푠 표푓 푒푥푝표푠푢푟푒 푎푚표푛푔 푐푎푠푒푠 Prevalence Odds Ratio = 푂푑푑푠 표푓 푒푥푝표푠푢푟푒 푎푚표푛푔 푛표푛−푐푎푠푒푠 퐴 퐵 퐴 × 퐷 = ÷ = 퐶 퐷 퐵 × 퐶 31 No OA Example: OA knee and Obesity OA Knee Knee Total Obesity 80 20 100 No 40 60 100 Obesity No OA 120 80 200 OA Knee Knee Total Prevalence of OA knee 120 / 200 = 0.6 Obesity 80 20 100 Prevalence of OA knee among obese 80 / 100 = 0.8 subjects No Prevalence of OA knee among non-obese 40 / 100 = 0.4 40 60 100 subjects Obesity Prevalence Ratio 0.8 / 0.4 = 2.0 Interpretration: The probability of OA is 2 times higher for obese subjects than 120 80 200 non-obese subjects. OR the probability of OA is 100% higher for obese subjects than non-obese subjects. Prevalence odds ratio Odds ratio • The odds is the ratio of the probability that the • Probability of winning = 60% event of interest occurs to the probability that it • Odds of winning = ? does not. • This is often estimated by the ratio of the number of times that the event of interest occurs to the number of times that it does not 6 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies Odds ratio • Probability of winning = 60% • Odds of winning = 60% : 40% = P : 1-P = 0.6 : 1- 0.6 = 0.6 : 0.4 = 1.5 No OA Odds? OA Knee Knee Total Obesity 80 20 100 No 40 60 100 Obesity 120 80 200 Prevalence of OA knee 120 / 200 = 0.6 Prevalence of OA knee among obese 80 / 100 = 0.8 subjects Prevalence of OA knee among non-obese 40 / 100 = 0.4 subjects Prevalence Ratio 0.8 / 0.4 = 2.0 Prevalence Odds Ratio 80:20 / 40:60 Probability of dying = 50% 80x60 / 20x40 = 6.0 Probability of living on = 50% Odds of dying = 50%:50% = 50/50 Prevalence Odds Ratio Usefulness of Cross-sectional study Prevalence Odds Ratio • Community 80 × 60 • = = 6.0 Screening (normal population) 20 × 40 • Health status • Associations between variables Interpretation: The ratio of the odds of having OA • Surveillance: repeated cross-sectional studies in the obese group relative to the odds in favor of • Clinical practice having OA in non-obese group. • Diagnostic study (illness) 42 7 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies When we found association… Hill’s causal criteria • Spuriousness or artifact Facet Series • Confounding Control Case Cross Case Studies Studies Cohort Studies Randomized Controlled Trials • Chance Sectional • Causation Temporality X X √ √ √ Strength X Up to the result Dose-response X Up to the result Consistency X Up to the result Biologic Plausibility N/A Reversibility N/A Specificity N/A Analogy N/A Experimental evidence X X X X √ Advantages Disadvantages of cross-sectional studies of cross-sectional studies (1) • Good for describing the magnitude and • Length biased sampling: diseases that have distribution of health problems. long duration will over-represent the magnitude • Generalizability. of illness while short duration will under- represent illness • Quick, conducted over short period of time, easy, inexpensive. • Can study multiple exposures and disease • Prevalent rather than incident cases of disease outcomes simultaneously. are identified – exposures may be associated with survival rather than risk of development of disease. 45 46 Disadvantages Disadvantages of cross-sectional studies (2) of cross-sectional studies (3) • Difficult to separate cause from effect, because • Confounding factors may not be equally measurement of exposure and outcome are distributed between the groups being compared conducted at the same time (difficult to and this unequal distribution may lead to bias establish temporal relationship) and subsequent misinterpretation. • Can assess only association but not a “causal association”. 47 48 8 Case Series, Descriptive, and Cross-Sectional 6-Aug-14 Studies Bias in Cross-Sectional Studies 1. Selection bias - Sampling bias - Response and non-response bias 2. Information bias Section for Clinical Epidemiology & Biostatistics 3. Confounding Faculty of Medicine Ramathibodi Hospital facebook.com/ramaclinicalepi www.ceb-rama.org 49 9.
Load more

Recommended publications
  • TUTORIAL in BIOSTATISTICS: the Self-Controlled Case Series Method
    STATISTICS IN MEDICINE Statist. Med. 2005; 0:1–31 Prepared using simauth.cls [Version: 2002/09/18 v1.11] TUTORIAL IN BIOSTATISTICS: The self-controlled case series method Heather J. Whitaker1, C. Paddy Farrington1, Bart Spiessens2 and Patrick Musonda1 1 Department of Statistics, The Open University, Milton Keynes, MK7 6AA, UK. 2 GlaxoSmithKline Biologicals, Rue de l’Institut 89, B-1330 Rixensart, Belgium. SUMMARY The self-controlled case series method was developed to investigate associations between acute outcomes and transient exposures, using only data on cases, that is, on individuals who have experienced the outcome of interest. Inference is within individuals, and hence fixed covariates effects are implicitly controlled for within a proportional incidence framework. We describe the origins, assumptions, limitations, and uses of the method. The rationale for the model and the derivation of the likelihood are explained in detail using a worked example on vaccine safety. Code for fitting the model in the statistical package STATA is described. Two further vaccine safety data sets are used to illustrate a range of modelling issues and extensions of the basic model. Some brief pointers on the design of case series studies are provided. The data sets, STATA code, and further implementation details in SAS, GENSTAT and GLIM are available from an associated website. key words: case series; conditional likelihood; control; epidemiology; modelling; proportional incidence Copyright c 2005 John Wiley & Sons, Ltd. 1. Introduction The self-controlled case series method, or case series method for short, provides an alternative to more established cohort or case-control methods for investigating the association between a time-varying exposure and an outcome event.
    [Show full text]
  • Supplementary File
    Supplementary file Table S1. Characteristics of studies included in the systematic review. Authors, reference Type of article Number of patients Type of stroke Valderrama [1] case report 1 AIS Oxley [2] case series 5 AIS Morassi [3] case series 6 AIS (n = 4), HS (n = 2) Tunc [4] case series 4 AIS Avula [5] case series 4 AIS (n = 3), TIA (n = 1) Oliver [6] case report 1 AIS Beyrouti [7] case series 6 AIS Al Saiegh [8] case series 2 AIS (n = 1), SAH (n = 1) Gunasekaran [9] case report 1 AIS Goldberg [10] case report 1 AIS Viguier [11] case report 1 AIS Escalard [12] case series/ case control 10 AIS Wang [13] case series 5 AIS Fara [14] case series 3 AIS Moshayedi [15] case report 1 AIS Deliwala [16] case report 1 AIS Sharafi-Razavi [17] case report 1 HS retrospective cohort study (case Jain [18] 35 AIS (n = 26) HS (n = 9) control) retrospective cohort study (case Yaghi [19] 32 AIS control) AIS (n = 35), TIA (n = 5), HS Benussi [20] retrospective cohort study 43 (n = 3) Rudilosso [21] case report 1 AIS Lodigiani [22] retrospective cohort study 9 AIS Malentacchi [23] case report 1 AIS J. Clin. Med. 2020, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/jcm J. Clin. Med. 2020, 9, x FOR PEER REVIEW 2 of 8 retrospective cohort study/case Scullen [24] 2 HS + AIS (n = 1), AIS (n = 1) series retrospective cohort study/ case AIS (n = 17), ST (n = 2), HS Sweid [25] 22 series (n = 3) AIS – acute ischemic stroke; HS – haemorrhagic stroke; SAH – subarachnoid haemorrhage; ST – sinus thrombosis; TIA-transient ischemic attack.
    [Show full text]
  • Chronic Lymphocytic Leukemia in a Black
    L OPEN ACCESS Freely available online al of euk rn em u i o a J Journal of Leukemia ISSN: 2329-6917 Case Report Chronic Lymphocytic Leukemia in A Black African Man: A Cameroonian Case Report Raspail Carrel Founou1*, Julius Nwobegahay2, Regine Gandji3, Cedrice Tsayem4, Sandra Yopa5, Martin Kuete6 and Luria Leslie Founou7 1Department of Clinical Microbiology, Centre of Expertise and Biological Diagnostic of Cameroon (CEDBCAM), Yaounde, Cameroon; 2Military Health Research Centre (CRESAR), Yaounde, Cameroon; 3Department of Biological Sciences, Higher Institute of Medical Technology, Yaoundé, Cameroon; 4Department of Clinical Biochemistry, Centre of Expertise and Biological Diagnostic of Cameroon (CEDBCAM), Yaounde, Cameroon; 5Department of Emergency, District Hospital of Biyem-Assi, Yaounde, Cameroon; 6Department of Biomedical and Applied Health, Faculty of Health Sciences, Université des Montagnes, Bangante, Cameroon; 7Department of Food Safety and Environmental Microbiology, Centre of Expertise and Biological Diagnostic of Cameroon (CEDBCAM), Yaounde, Cameroo ABSTRACT Chronic Lymphocytic Leukemia (CLL) is an acquired monoclonal disorder characterized by a gradual accumulation of functionally incompetent lymphocytes. It generally presents a clonal B cells arrested in the B-cell differentiation pathway that resemble morphologically to mature lymphocytes in the peripheral blood. There is a scarcity of CLL data among sub-Saharan African countries such as Cameroon. We herein report a case of CLL that remained stable over a period of seven years in a 54 years old Black African man. The patient had no history of exposure to toxic chemicals or ionizing radiation and presented with several complaints and clinical symptoms. Clinical and laboratory investigations indicated a CLL in stage B of the Binet staging system.
    [Show full text]
  • Case Series: COVID-19 Infection Causing New-Onset Diabetes Mellitus?
    Endocrinology & Metabolism International Journal Case Series Open Access Case series: COVID-19 infection causing new-onset diabetes mellitus? Abstract Volume 9 Issue 1 - 2021 Objectives: This paper seeks to explore the hypothesis of the potential diabetogenic effect 1 2 of SARS-COV-2 (Severe Acute respiratory syndrome coronavirus). Rujuta Katkar, Narasa Raju Madam 1Consultant Endocrinologist at Yuma Regional Medical Center, Case series presentation: We present a case series of observation among 8 patients of age USA 2 group ranging from 34 to 74 years with a BMI range of 26.61 to 53.21 Kilogram/square Hospitalist at Yuma Regional Medical Center, USA meters that developed new-onset diabetes after COVID-19 infection. Correspondence: Rujuta Katkar, MD, Consultant Severe Acute Respiratory Syndrome Coronavirus (SARS-COV-2), commonly known as Endocrinologist at Yuma Regional Medical Center, 2851 S Coronavirus or COVID-19(Coronavirus infectious disease), gains entry into the cells by Avenue B, Bldg.20, Yuma, AZ-85364, USA, Tel 2034359976, binding to the Angiotensin-converting enzyme-2(ACE-2) receptors located in essential Email metabolic tissues including the pancreas, adipose tissue, small intestine, and kidneys. Received: March 25, 2021 | Published: April 02, 2021 The evidence reviewed from the scientific literature describes how ACE 2 receptors play a role in the pathogenesis of diabetes and the plausible interaction of SARS-COV-2 with ACE 2 receptors in metabolic organs and tissues. Conclusion: The 8 patients without a past medical history of diabetes admitted with COVID-19 infection developed new-onset diabetes mellitus due to plausible interaction of SARS-COV-2 with ACE 2 receptors.
    [Show full text]
  • Observational Clinical Research
    E REVIEW ARTICLE Clinical Research Methodology 2: Observational Clinical Research Daniel I. Sessler, MD, and Peter B. Imrey, PhD * † Case-control and cohort studies are invaluable research tools and provide the strongest fea- sible research designs for addressing some questions. Case-control studies usually involve retrospective data collection. Cohort studies can involve retrospective, ambidirectional, or prospective data collection. Observational studies are subject to errors attributable to selec- tion bias, confounding, measurement bias, and reverse causation—in addition to errors of chance. Confounding can be statistically controlled to the extent that potential factors are known and accurately measured, but, in practice, bias and unknown confounders usually remain additional potential sources of error, often of unknown magnitude and clinical impact. Causality—the most clinically useful relation between exposure and outcome—can rarely be defnitively determined from observational studies because intentional, controlled manipu- lations of exposures are not involved. In this article, we review several types of observa- tional clinical research: case series, comparative case-control and cohort studies, and hybrid designs in which case-control analyses are performed on selected members of cohorts. We also discuss the analytic issues that arise when groups to be compared in an observational study, such as patients receiving different therapies, are not comparable in other respects. (Anesth Analg 2015;121:1043–51) bservational clinical studies are attractive because Group, and the American Society of Anesthesiologists they are relatively inexpensive and, perhaps more Anesthesia Quality Institute. importantly, can be performed quickly if the required Recent retrospective perioperative studies include data O 1,2 data are already available.
    [Show full text]
  • Generating Real-World Evidence by Strengthening Real-World Data Sources
    Generating Real-World Evidence by Strengthening Real-World Data Sources Using “real-world evidence” to bring new “Every day, health care professionals are updating patients’ treatments to patients as part of the 21st electronic health records with data on clinical outcomes Century Cures Act (the “Cures Act”) is a key resulting from medical interventions used in routine clinical priority for the Department of Health and practice. As our experience with new medical products Human Services (HHS). Specifically, the Cures expands, our knowledge about how to best maximize their Act places focus on the use of real-world data benefits and minimize potential risks sharpens with each data to support regulatory decision-making, including point we gather. Every clinical use of a product produces data the approval of new indications for existing that can help better inform us about its safety and efficacy.” drugs in order to make drug development faster jacqueline corrigan-curay, md, jd and more efficient. As such, the Cures Act director of the office of medical policy in fda’s center for drug evaluation and research has tasked the Food and Drug Administration (FDA) to develop a framework and guidance for evaluating real-world evidence in the context of drug regulation.1 Under the FDA’s framework, real-world evidence (RWE) is generated by different study designs or analyses, including but not limited to, randomized trials like large simple trials, pragmatic trials, and observational studies. RWE is the clinical evidence about the use, potential benefits, and potential risks of a medical product based on an analysis of real-world data (RWD).
    [Show full text]
  • Autopsy Case Report and Review of the Literature Karyna C
    Fatal Neonatal Echovirus 6 Infection: Autopsy Case Report and Review of the Literature Karyna C. Ventura, M.D., Hal Hawkins, M.D., Ph.D., Michael B. Smith, M.D., David H. Walker, M.D. Department of Pathology, University of Texas Medical Branch, Galveston, Texas CASE REPORT A full-term, healthy male neonate was delivered by caesarian section to a 26-year-old primigravida A full-term boy appropriate for his gestational age woman who had a history of fever and upper respi- was born via caesarian section to a 26-year-old G1P0 ratory tract infection. On the fourth day of life, the Latin American woman who had a medical history of a well-controlled seizure disorder for which she was neonate developed a sepsis-like syndrome, acute receiving carbamazepine. She had received regular respiratory and renal failure, and disseminated in- prenatal care, with negative prenatal serologic tests travascular coagulopathy. He died 13 days after for human immunodeficiency virus, hepatitis B virus, birth. Postmortem examination revealed jaundice, and syphilis. Two weeks before delivery, she experi- anasarca, massive hepatic necrosis, adrenal hemor- enced fever and an upper respiratory tract infection. rhagic necrosis, renal medullary hemorrhage, hem- At birth, the infant weighed 3838 g and had an Apgar orrhagic noninflammatory pneumonia, and severe score of 9. The neonate was put under an oxygen encephalomalacia. Echovirus type 6 was isolated hood, then was later slowly weaned from it. On his from blood, liver, and lungs. Although uncommon, fourth day of life, the neonate developed fever echovirus type 6 infection may produce a spectrum (38.6°C) and was observed to have decreased activity.
    [Show full text]
  • The Value of Case Reports in Systematic Reviews from Rare Diseases
    International Journal of Environmental Research and Public Health Article The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II) Miguel Sampayo-Cordero 1,2,*, Bernat Miguel-Huguet 3, Andrea Malfettone 1,2, José Manuel Pérez-García 1,2,4, Antonio Llombart-Cussac 1,2,5, Javier Cortés 1,2,4,6, Almudena Pardo 7 and Jordi Pérez-López 8 1 Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ 07450, USA; [email protected] (A.M.); [email protected] (J.M.P.-G.); [email protected] (A.L.-C.); [email protected] (J.C.) 2 Medica Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain 3 Department of Surgery, Hospital de Bellvitge, L’Hospitalet de Llobregat, 08907 Barcelona, Spain; [email protected] 4 Institute of Breast Cancer, Quiron Group, 08023 Barcelona, Spain 5 Hospital Arnau de Vilanova, Universidad Católica de Valencia “San Vicente Mártir”, 46015 Valencia, Spain 6 Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain 7 Albiotech Consultores y Redacción Científica S.L., 28035 Madrid, Spain; [email protected] 8 Department of Internal Medicine, Hospital Vall d’Hebron, 08035 Barcelona, Spain; [email protected] * Correspondence: [email protected] Received: 3 August 2020; Accepted: 7 September 2020; Published: 10 September 2020 Abstract: Background: Case reports are usually excluded from systematic reviews. Patients with rare diseases are more dependent on novel individualized strategies than patients with common diseases. We reviewed and summarized the novelties reported by case reports in mucopolysaccharidosis type II (MPS-II) patients treated with enzyme replacement therapy (ERT).
    [Show full text]
  • Download, And
    medRxiv preprint doi: https://doi.org/10.1101/19002121; this version posted July 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Evaluation of Indicators of Reproducibility and Transparency in Published Cardiology Literature Short Title: Anderson et al.; Indicators of Reproducibility in Cardiology J. Michael Anderson, B.S.1, Bryan Wright, B.G.S.1, Daniel Tritz, B.S.1, Jarryd Horn, B.S.1, Ian Parker, D.O.2, Daniel Bergeron, D.O.2, Sharolyn Cook, D.O.2, Matt Vassar, PhD1 1. Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA 2. Oklahoma State University Medical Center - Department of Cardiology, Tulsa, Oklahoma, USA Corresponding Author: Mr. J. Michael Anderson, Oklahoma State University Center for Health Sciences, 1111 W 17th St Tulsa, OK 74107, United States; Fax: 918-561-8428; Telephone: 918-521-8774; Email: [email protected] Word Count: 7041 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/19002121; this version posted July 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract: Background The extent of reproducibility in cardiology research remains unclear. Therefore, our main objective was to determine the quality of research published in cardiology journals using eight indicators of reproducibility.
    [Show full text]
  • Repeatability Case Study of the 3D Printer in the School of Engineering and Applied Science Lab Naif Faleh S
    Western Kentucky University TopSCHOLAR® Masters Theses & Specialist Projects Graduate School Spring 2018 Repeatability Case Study of the 3D Printer in the School of Engineering and Applied Science Lab Naif Faleh S. Albaiji Western Kentucky University, [email protected] Follow this and additional works at: https://digitalcommons.wku.edu/theses Part of the Ergonomics Commons, Industrial Engineering Commons, Operational Research Commons, and the Other Operations Research, Systems Engineering and Industrial Engineering Commons Recommended Citation Albaiji, Naif Faleh S., "Repeatability Case Study of the 3D Printer in the School of Engineering and Applied Science Lab" (2018). Masters Theses & Specialist Projects. Paper 2359. https://digitalcommons.wku.edu/theses/2359 This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Masters Theses & Specialist Projects by an authorized administrator of TopSCHOLAR®. For more information, please contact [email protected]. REPEATABILITY CASE STUDY OF THE 3D PRINTER IN THE SCHOOL OF ENGINEERING AND APPLIED SCIENCES LAB A Thesis Presented to The Faculty of the School of Engineering and Applied Science Western Kentucky University Bowling Green, Kentucky In Partial Fulfillment Of the Requirements for the Degree Master of Science By Naif Albaiji May 2018 I dedicate this thesis to my family, especially my mother, Laila Altaie, my father, Faleh, and my brother, Fawaz Albaiji. They have supported me since day one to ensure that I find my way to success. I also dedicate this work to the School of Engineering and Applied Science, my thesis committee, and my professors who have guided me. ACKNOWLEDGMENTS I would like to thank several people who inspired and helped me throughout my journey with this study and degree: Dr.
    [Show full text]
  • EPI Case Study 1 Incidence, Prevalence, and Disease
    EPIDEMIOLOGY CASE STUDY 1: Incidence, Prevalence, and Disease Surveillance; Historical Trends in the Epidemiology of M. tuberculosis STUDENT VERSION 1.0 EPI Case Study 1: Incidence, Prevalence, and Disease Surveillance; Historical Trends in the Epidemiology of M. tuberculosis Estimated Time to Complete Exercise: 30 minutes LEARNING OBJECTIVES At the completion of this Case Study, participants should be able to: ¾ Explain why denominators are necessary when comparing changes in morbidity and mortality over time ¾ Distinguish between incidence rates and prevalence ratios ¾ Calculate and interpret cause-specific morbidity and mortality rates ¾ Describe how changes in mortality or morbidity could be due to an artifact rather than a real change ASPH EPIDEMIOLOGY COMPETENCIES ADDRESSED C. 3. Describe a public health problem in terms of magnitude, person, place, and time C. 6. Apply the basic terminology and definitions of epidemiology C. 7. Calculate basic epidemiology measures C. 9. Draw appropriate inference from epidemiologic data C. 10. Evaluate the strengths and limitations of epidemiologic reports ASPH INTERDISCIPLINARY/CROSS-CUTTING COMPETENCIES ADDRESSED F.1. [Communication and Informatics] Describe how the public health information infrastructure is used to collect, process, maintain, and disseminate data J.1. [Professionalism] Discuss sentinel events in the history and development of the public health profession and their relevance for practice in the field L.2. [Systems Thinking] Identify unintended consequences produced by changes made to a public health system This material was developed by the staff at the Global Tuberculosis Institute (GTBI), one of four Regional Training and Medical Consultation Centers funded by the Centers for Disease Control and Prevention. It is published for learning purposes only.
    [Show full text]
  • Study Types Transcript
    Study Types in Epidemiology Transcript Study Types in Epidemiology Welcome to “Study Types in Epidemiology.” My name is John Kobayashi. I’m on the Clinical Faculty at the Northwest Center for Public Health Practice, at the School of Public Health and Community Medicine, University of Washington in Seattle. From 1982 to 2001, I was the state epidemiologist for Communicable Diseases at the Washington State Department of Health. Since 2001, I’ve also been the foreign adviser for the Field Epidemiology Training Program of Japan. About this Module The modules in the epidemiology series from the Northwest Center for Public Health Practice are intended for people working in the field of public health who are not epidemiologists, but who would like to increase their understanding of the epidemiologic approach to health and disease. This module focuses on descriptive and analytic epide- miology and their respective study designs. Before you go on with this module, we recommend that you become familiar with the following modules, which you can find on the Center’s Web site: What is Epidemiology in Public Health? and Data Interpretation for Public Health Professionals. We introduce a number of new terms in this module. If you want to review their definitions, the glossary in the attachments link at the top of the screen may be useful. Objectives By now, you should be familiar with the overall approach of epidemiology, the use of various kinds of rates to measure disease frequency, and the various ways in which epidemiologic data can be presented. This module offers an overview of descriptive and analytic epidemiology and the types of studies used to review and investigate disease occurrence and causes.
    [Show full text]